406 related articles for article (PubMed ID: 24329798)
1. Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
Butler MO; Hirano N
Immunol Rev; 2014 Jan; 257(1):191-209. PubMed ID: 24329798
[TBL] [Abstract][Full Text] [Related]
2. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
3. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
4. Transient stimulation expands superior antitumor T cells for adoptive therapy.
Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
[TBL] [Abstract][Full Text] [Related]
5. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
7. Engineered T cells for anti-cancer therapy.
Turtle CJ; Hudecek M; Jensen MC; Riddell SR
Curr Opin Immunol; 2012 Oct; 24(5):633-9. PubMed ID: 22818942
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy: good habits instilled at youth have long-term benefits.
Paulos CM; Suhoski MM; Plesa G; Jiang T; Basu S; Golovina TN; Jiang S; Aqui NA; Powell DJ; Levine BL; Carroll RG; Riley JL; June CH
Immunol Res; 2008; 42(1-3):182-96. PubMed ID: 18949448
[TBL] [Abstract][Full Text] [Related]
9. Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens.
Jæhger DE; Hübbe ML; Kræmer MK; Clergeaud G; Olsen AV; Stavnsbjerg C; Wiinholt MN; Kjær A; Henriksen JR; Hansen AE; Andresen TL
Sci Rep; 2021 Oct; 11(1):19794. PubMed ID: 34611284
[TBL] [Abstract][Full Text] [Related]
10. Artificial antigen-presenting cells for use in adoptive immunotherapy.
Turtle CJ; Riddell SR
Cancer J; 2010; 16(4):374-81. PubMed ID: 20693850
[TBL] [Abstract][Full Text] [Related]
11. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
Chmielewski M; Hombach AA; Abken H
Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
[TBL] [Abstract][Full Text] [Related]
12. Role of memory T cell subsets for adoptive immunotherapy.
Busch DH; Fräßle SP; Sommermeyer D; Buchholz VR; Riddell SR
Semin Immunol; 2016 Feb; 28(1):28-34. PubMed ID: 26976826
[TBL] [Abstract][Full Text] [Related]
13. The use of endogenous T cells for adoptive transfer.
Yee C
Immunol Rev; 2014 Jan; 257(1):250-63. PubMed ID: 24329802
[TBL] [Abstract][Full Text] [Related]
14. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.
Rushworth D; Jena B; Olivares S; Maiti S; Briggs N; Somanchi S; Dai J; Lee D; Cooper LJ
J Immunother; 2014 May; 37(4):204-13. PubMed ID: 24714354
[TBL] [Abstract][Full Text] [Related]
15. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.
Denman CJ; Senyukov VV; Somanchi SS; Phatarpekar PV; Kopp LM; Johnson JL; Singh H; Hurton L; Maiti SN; Huls MH; Champlin RE; Cooper LJ; Lee DA
PLoS One; 2012; 7(1):e30264. PubMed ID: 22279576
[TBL] [Abstract][Full Text] [Related]
16. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
17. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy.
Temme A; Schmitz M
Immunotherapy; 2016 Sep; 8(9):983-6. PubMed ID: 27485071
[No Abstract] [Full Text] [Related]
19. Engineering T cells for adoptive therapy: outsmarting the tumor.
Kunert A; Debets R
Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
[TBL] [Abstract][Full Text] [Related]
20. Engineering T cells for cancer: our synthetic future.
Vonderheide RH; June CH
Immunol Rev; 2014 Jan; 257(1):7-13. PubMed ID: 24329786
[No Abstract] [Full Text] [Related]
[Next] [New Search]
